Triple-negative breast cancer: are we making headway at least?
Open Access
- 30 April 2012
- journal article
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 4 (4), 195-210
- https://doi.org/10.1177/1758834012444711
Abstract
The so-called triple-negative breast cancer, as defined by tumors that lack estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 (HER2) overexpression, has generated growing interest in recent years despite representing less than 20% of all breast cancers. These tumors constitute an important clinical challenge, as they do not respond to endocrine treatment and other targeted therapies. As a group they harbor an aggressive clinical phenotype with early development of visceral metastases and a poor long-term prognosis. While chemotherapy remains effective in triple-negative disease, research continues to further identify potential new targets based on phenotypical and molecular characteristics of these tumors. In this respect, the presence of a higher expression of different biomarkers including epidermal growth factor receptor, vascular endothelial growth factor receptor, fibroblast growth factor receptor and Akt activation has led to a proliferation of clinical trials assessing the role of inhibitors to these pathways in triple-negative tumors. Moreover, the described overlap between triple-negative and basal-like tumors, and the similarities with tumors arising in the BRCA1 mutation carriers has offered potential therapeutic avenues for patients with these cancers including poly (ADP-ribose) polymerase inhibitors and a focus on a higher sensitivity to alkylating chemotherapy agents. Results from these trials have shown some benefit in small subgroups of patients, even in single-agent therapy, which reflects the heterogeneity of triple-negative breast cancer and highlights the need for a further subclassification of these types of tumors for better prognosis identification and treatment individualization.Keywords
This publication has 95 references indexed in Scilit:
- Biology-Driven Phase II Trials: What Is the Optimal Model for Molecular Selection?Journal of Clinical Oncology, 2011
- Implications of personalized medicine—perspective from a cancer centerNature Reviews Clinical Oncology, 2011
- Secretory breast carcinomas with ETV6-NTRK3 fusion gene belong to the basal-like carcinoma spectrumLaboratory Investigation, 2009
- Sites of distant recurrence and clinical outcomes in patients with metastatic triple‐negative breast cancerCancer, 2008
- Invasive ductal carcinoma of the breast with the “triple-negative” phenotype: prognostic implications of EGFR immunoreactivityBreast Cancer Research and Treatment, 2008
- The combination of high cyclin E and Skp2 expression in breast cancer is associated with a poor prognosis and the basal phenotypeHuman Pathology, 2008
- Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patientsBreast Cancer Research and Treatment, 2007
- Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotypeCancer, 2007
- Prognostic markers in triple‐negative breast cancerCancer, 2006
- Hallmarks of 'BRCAness' in sporadic cancersNature Reviews Cancer, 2004